RPL17 and cancer: The suppression of anti-tumour immunity in precancerous lesions through the PD-1/PD-L1 pathway may cause cancer progression from the equilibrium to the escape phase, causing the invasion of dysplastic epithelial cells into stromal tissue or malignant transformation.